Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Triboelectric Nanogenerators Printed from Composite Inks for Energy Harvesting (NanoHarvest)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Portugal
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2023-07-03
End date: 2025-07-02
Duration (months): 24.0
Total project cost (EUR): 164676.56
EU funding (EUR): 164676.56
Participants: 1
Project status: CLOSED

Triboelectric nanogenerators have recently emerged as a very promising energy harvesting technique for transforming mechanical energy into electrical energy. Their emergence is especially timely as the world undergoes a sustainable energy revolution and these devices have successfully demonstrated energy harvesting from a vast range of applications from wind to wave to wearable textiles. Importantly, they can also be fabricated from common materials such as paper, polymers, and graphite. However, as most highly triboelectric materials are polymeric, they suffer from low currents and brittleness under friction, with high performances usually only achieved using complex materials with a large number of processing stages. These are major challenges that are preventing the widespread and long-term application of these devices. This project will simultaneously address all of these issues by developing a printable polymeric composite containing 1D carbon nanotubes (to improve both mechanical strength & electrical conduction) and 2D nanosheets of molybdenum disulphide (to improve the charge retention & operation lifetime) which, in combination with a paper-based tribopositive layer, will form the basis of a low-cost, high performance & robust triboelectric nanogenerator. Crucially, as this composite will be printable it will be compatible with scalable processes such as roll-to-roll or flexographic printing. Success here will be achieved by combining the applicant's expertise on printable nanomaterials with the supervisor's knowledge and background on triboelectric generation and energy-storage devices. We will also demonstrate the practical utility of these devices by printing a device capable of harvesting energy from a bicycle tyre under cycling conditions. The creation of an optimised ink in combination with additive manufacturing techniques means we will be easily able to print devices that can ultimately be integrated into a wide range of harvesting applications.

Keywords: triboelectric nanogenerators,printed electronics
MEMBRANE SCALE UP FOR CHEMICAL INDUSTRIES (MEASURED)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Digital, Industry and Space
Theme: Industry
Destination: Increased Autonomy in Key Strategic Value Chains for Resilient Industry
Action type: Innovation actions
Countries involved: Netherlands,Spain,Slovenia,Italy,Germany,France,Sweden
Call: Membranes for gas separations - membrane distillation (IA) (HORIZON-CL4-2022-RESILIENCE-01, 2022)
Start date: 2023-01-01
End date: 2026-12-31
Duration (months): 48.0
Total project cost (EUR): 9515182.9
EU funding (EUR): 7971409.0
Participants: 18
Project status: SIGNED

The project MEASURED aims at developing and demonstrating at TRL7 advanced membrane materials for Pervaporation (PV), Membrane Distillation (MD) and Gas Separation (GS) technologies applied to acrylic ester production, membrane manufacturing and gas separation from a carbon capture & utilization (CCU) stream. PV targets 1 m2 of membrane processing H2O flux > 1.0 kg/m2·hr using a 55-channel tube in the industrial setting of ARKEMA, a stability > 90% over 3 months of testing, resulting in a CAPEX 30% lower compared to current cost - from 2100 €/m2 to 1500 €/m2. MD aims at treating the daily amount of generated wastewater (70 L/h) from the manufacturing facility of PVDF membranes at GVS Spa with energy supply via about 100 Solar/Photovoltaic collectors, showing higher chemical resistance (> 10%), >25% reduction of water footprint, permeability of reused MD for Microfiltration > 500 L/m2·hr·bar. GS prototype will be scaled-up to a membrane area of 1.2 m2/module using a 61-channel tube installed downstream the GAYA methanation unit of Engie, reducing the membrane cost (produced at large scale) from 1944 €/m2 to 795 €/m2 (almost 60%). At the end of the project, the integrated MEASURED technologies will reach a TRL7 demonstration over 20,000 hours operation under (industrial) operational conditions. MEASURED includes a thorough multiscale modelling and simulation techniques including a full Life Cycle Assessment and addresses the societal implications to increase the acceptance and further market readiness. The interdisciplinary consortium – overall 17 participants: 2 SMEs, 7 industries and 8 Universities/research centers – will comprehensively study the development of advanced materials, reactor design and process configuration to identify the most sustainable options from a demonstration, techno-economic and environmental point of view.

Keywords: membranes membrane modules membrane processes prototype demonstration pervaporation membrane distillation gas separation
Valuing the Wild: From Stated Preference Methods to Compensating Income Variation (WILDVALUE)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Economic Sciences
Countries involved: Finland
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2026-08-01
End date: 2028-07-31
Duration (months): 24.0
Total project cost (EUR): 242116.8
EU funding (EUR): 242116.8
Participants: 1
Project status: SIGNED

Demand for endangered wildlife products is driving the illegal and unsustainable wildlife trade, which threatens global biodiversity and has significant impacts on public health through the transmission of zoonotic diseases across the world. The illegal wildlife trade is imperilling one quarter of the total terrestrial vertebrate species, pushing many species to the brink of extinction. The rising frequency of zoonotic epidemics and pandemics, with COVID-19 as the most recent example, has highlighted the devastating public health consequences that can result from wildlife consumption. In many Asian cultures, people use endangered wildlife products as traditional medicine to treat various diseases and health conditions, despite the availability of alternative treatments and modern medicines. Understanding people’s preferences, particularly their willingness to pay (WTP) for healthcare, is critical to inform public health policies and wildlife trade governance. Yet, few studies have been conducted on this important topic due to challenges in approaching consumers and limitations in existing non-market valuation methods, particularly preference-based methods. The two specific aims of WILDVALUE are: (1) to assess people’s preferences for healthcare and endangered wildlife products using the Compensating Income Variation (CIV) method and (2) to advance the field of non-market valuation by comparing the CIV method to stated preference methods for the first time. WILDVALUE will improve wildlife trade governance, inform public health policies, and advance the field of non-market valuation through a unique research on the consumption of endangered wildlife products for health-related purposes.

Keywords: non market valuation,compensating income variation,stated preference methods,illegal wildlife trade,traditional asian medicine
SYNergic multimodal platform for high-throughput anti-cancer bOne-metastases theraPy ScreenIngS (SYNOPSIS)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Italy,Switzerland
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2026-06-01
End date: 2029-05-31
Duration (months): 36.0
Total project cost (EUR): 412700.52
EU funding (EUR): 412700.52
Participants: 2
Project status: SIGNED

Cancer is currently the second cause of death worldwide; however, the World Health Organization expects it to become the first one by 2060. Breast and Prostate Cancers (BC and PC) are highly aggressive tumours linked to top cancer-related mortality rates in the world, with the skeletal tissue as one of the primary sites of metastasis. This project, called SYNOPSIS, an acronym for “SYNergic multimodal platform for high-throughput anti-cancer bOne-metastases theraPy ScreenIngS”, aims at studying therapeutic agents against BC and PC in the perivascular niche around the bone-tissue within a lab-on-chip, with a multimodal approach involving time-lapse microscopy (TLM) and impedance optical-deformability cytometry (IODC). The proposed project is divided into four key phases: 1. Organ-on-chip platform: design, fabrication, and testing of the microphysiological system (MPS), including the culturing of bone and cancer cells under fluid shear stress conditions and the administration of chemotherapeutic agents. 2. IODC: design, fabrication, and testing of the module. 3. Data acquisition: TLM videos of the cells in the MPS and IODC measurements. 4. Data Analysis: optimise processing strategies for TLM and IODC data to leverage the various signals available for evaluating therapy efficacy. The action will bring: (1) a new MPS, mimicking cancer in the bone perivascular niche, overcoming literature’s limitations; (2) a novel IODC platform probing cell’s electro-mechanical features; (3) a first-time combination of TLM and IODC measurements in MPS. The principal objective of this action will be the realization of a multimodal platform for anti-cancer bone-metastases drug-efficacy evaluation (4), combining TLM video, IODC with a minimum of 10^3 cells/s, and data analysis reaching 95% accuracy on test data coming from independent experiments, providing the user with the rationale of the decision process, finally decreasing cancer-related mortality.

Keywords: lab on chip,time lapse microscopy,impedance cytometry,deformability cytometry,drug screening
HYBRID AND ADVANCED MACHINE LEARNING PLATFORM FOR MANUFACTURING, ENGINEERING, AND RESEARCH @ HLRS (HammerHAI)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Digital, Industry and Space
Theme: Public-private partnerships
Destination: European High Performance Computing
Action type: Research and Innovation actions
Partnership: EUROHPC (JU-JTI)
Countries involved: Germany
Call: Artificial Intelligence Factories (HORIZON-JU-EUROHPC-2025-AI-01-IBA, 2025)
Start date: 2025-04-01
End date: 2028-03-31
Duration (months): 36.0
Total project cost (EUR): 11833707.5
EU funding (EUR): 5916853.77
Participants: 5
Project status: SIGNED

The HammerHAI project offers to establish an AI Factory at the High-Performance Computing Center Stuttgart (USTUTT/HLRS), which is supported by a strong consortium from Germany, to successfully meet the growing demand for artificial intelligence (AI) infrastructure across Europe. HammerHAI will be a one-stop shop for many AI users, focusing primarily on start-ups, small and medium-sized enterprises (SMEs), large industrial companies, and supporting academic institutions and the public sector. It will offer tailored services and infrastructure to accelerate AI innovation and help develop a competitive AI ecosystem in Europe. The AI Factory will be located in a region that is one of Europe’s powerhouses in manufacturing and engineering innovation, and it will be integrated into an ecosystem that promotes talent building that will be the basis of an ongoing digital transition. The AI Factory HammerHAI will provide secure, scalable, and AI-optimised supercomputing resources to meet the needs of start-ups, SMEs, industry, and research institutions. Its infrastructure will enable users to easily migrate their AI applications from laptops or cloud environments to supercomputers, providing the computing power needed to develop large-scale AI models. Hereby, the AI Factory will support the entire AI lifecycle, from data preparation to model training, deployment, monitoring, and retraining, and will provide a comprehensive package of services to ensure efficient and effective AI development and operation. HammerHAI will meet Europe's growing demand for sovereign AI products by providing scalable, secure, and AI-optimised supercomputing infrastructure integrated into an existing research, education, and innovation ecosystem. HammerHAI will fast-track start-ups, professionals, SMEs, industries, and research to realise the full potential of AI.

Keywords: artificial intelligence supercomputing
Inhalable therapeutic nanoformulations for non-invasive and selective treatments of the diseased heart (NP-MP1)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Italy
Call: EIC Accelerator Open 2024 (HORIZON-EIC-2024-ACCELERATOR-02, 2024)
Start date: 2025-06-01
End date: 2027-05-31
Duration (months): 24.0
Total project cost (EUR): 3571427.14
EU funding (EUR): 2499999.0
Participants: 1
Project status: SIGNED

NanoPhoria bioscience leads the way in the development of groundbreaking inhalable cardiovascular treatments by combining innovative biologic drugs with a unique nanoparticle-mediated delivery platform. We seek EIC support to develop our lead product NP-MP1. This highly innovative lung-to-heart nano-in-micro peptide formulation has the potential to radically improve the treatment of Heart Failure with reduced Ejection Fraction (HFrEF), a chronic and largely unmet clinical condition affecting millions worldwide, with mortality and morbidity higher than most cancers. The peptide has proven safe and effective in restoring contractility in diseased cardiomyocytes, the cells responsible for heart to pumping. It modulates the L-type Calcium Channel, a key molecular player in excitation-contraction coupling, leading to the recovery of ejection fraction and halting HFrEF progression. Thanks to the patient-friendly inhalable formulation and the nano-carriers, the peptide can selectively and non-invasively reach the cardiomyocytes and perform its pharmacological action. Supported by solid proofs of concept in clinically relevant animal models, NP-MP1 offers a disease modifying mechanism of action and a targeted heart delivery, minimising accumulation in other organs and associated side effects: an approach not yet exploited in any clinical cardiovascular strategy. Therefore, NanoPhoria's solution is set to significantly improve life expectancy, quality of life and cost-effectiveness, outperforming competitors. The EIC project aims to further de-risk NP-MP1's development process, complete First-in-Human clinical trials and attract potential licensees/acquirers, bridging the gap between the current validation stage and the future exit. NanoPhoria's experienced team, collaboration with renowned academic institutions, CROs and CMOs, and established affiliations with distinguished cardiologists guarantee a successful pathway to clinical validation and commercial triumph.

Keywords: nanotechnology,nanoparticles,health related biotechnology,cardiovascular diseases,heart failure,hfref,inhalation,disease modifying drug,noninvasive treatment,patient friendly
A Novel Efficient And Scalable Wave Energy Generator, Pioneering Sustainable Power Generation (Arrecife)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Spain
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 60.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Arrecife Energy Systems is a pioneering wave energy company that has developed a breakthrough technology called Trimaran - a modular and scalable wave energy converter that can capture energy from both the potential and kinetic motion of ocean waves. Aiming to provide clean, renewable energy at an affordable cost, Arrecife's Trimaran represents a significant step forward in unlocking the enormous potential of wave energy. Its unique ability to mimic the behaviour of coral reefs allows it to harness energy from multi-directional wave patterns efficiently. This is achieved through a triangular configuration with two rows of turbines directly coupled to the generators leading to high efficiency in energy conversion as there are no intermediate mechanical components. One of the main advantages of the trimaran is its highly efficient energy generation. It can generate more energy than conventional wave energy converters by capturing both vertical and horizontal wave movements. In addition, the turbines are optimised for operation at the most common wave heights between 1 and 5 meters, ensuring a high capacity factor and maximising energy production throughout the year. The Trimaran's mooring system, which only requires a single line, significantly reduces installation and maintenance costs compared to competitors, which typically require 3 to 6 lines allowing usage in both inshore and offshore environments. Arrecife's solution offers a breakthrough potential to achieve the Levelized Cost of Electricity (LCOE), an important target set at 150 EUR/MWh by 2030 in the European SET plan for wave energy. Arrecife plans to increase energy conversion efficiency while reducing manufacturing and maintenance costs by continuously improving Trimaran's structure, turbines and components. Arrecife Energy Systems is poised to make a significant impact in realising affordable and clean power generation from the vast, untapped potential of ocean waves.

Keywords: wave energy,renewable energy,sustainable energy,wave energy converter,climate change mitigation
MULTIFUNCTIONAL MICROFLUIDIC PATCH FOR INFECTIOUS DISEASES DIAGNOSIS (FORTIFIEDx)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Digital, Industry and Space
Theme: Industry
Destination: Increased Autonomy in Key Strategic Value Chains for Resilient Industry
Action type: Research and Innovation actions
Countries involved: Belgium,Austria,Ireland,Germany,Poland,Guinea
Call: Smart and multifunctional biomaterials for health innovations (RIA) (HORIZON-CL4-2022-RESILIENCE-01, 2022)
Start date: 2023-08-01
End date: 2027-07-31
Duration (months): 48.0
Total project cost (EUR): 4986073.83
EU funding (EUR): 4986070.0
Participants: 9
Project status: SIGNED

In vitro diagnostic (IVD) technologies have revolutionized healthcare, yet remain confined to the laboratories. As witnessed during the COVID-19 pandemic, this traditional centralized approach was not sufficient to prevent and manage viral outbreak because it massively failed to deliver quick and cost-effective diagnosis. The ongoing pandemic further emphasizes the growing need to urgently bring lab-quality diagnosis to the hands of end users (i.e. point-of-care, POC). Despite high expectations from Lab-on-Chip technologies, they failed so far to disrupt the IVD market due to their complexity of integration/operation, high cost, off-chip sample preparation, poor scalability, to mention only a few. The FORTIFIEDx consortium aims to revolutionize the POC IVD field by making use of novel multifunctional biocompatible polymers and their (micro)structuring with mass fabrication technology to develop for the first time a true sample-to-result POC test. We will develop a FORTIFIEDx microfluidic-based patch capable of both biofluids (self-)sampling via hollow microneedles and immediate analysis of this sample on the very same patch in a completely self-powered manner. Two unmet clinical needs, posing epidemic/pandemic treats to both the developed and developing world, are selected: (1) sexually transmitted diseases, in particular simultaneous diagnosis of HIV and Syphilis, to enable timely diagnosis of patients not always able to reach centralized settings due to stigma or financial difficulties and (2) viral haemorrhagic fever, in particular Ebola and Lassa viruses, to battle their highly contagious and deadly outbreaks. To tackle this challenging aim, the interdisciplinary and experienced FORTIFIEDx consortium (2 universities, 5 research institutes and 2 SMEs from 6 countries) will combine insights from material science, engineering and microfabrication, microfluidic technology development, bioassay development, clinical validation and life cycle assessment.

Keywords: multifunctional biocompatible vitrimers,roll to roll fabrication,microfluidics,hollow microneedles,self sampling patch,in vitro diagnostics,point of care testing,infectious disease diagnosis
Waste recovery through the production of nanoparticles and biogas. (SMALLOPS)

Framework: Horizon Europe — Innovative Europe
Programme: European innovation ecosystems
Theme: Elevating the scalability potential of European business
Destination: Elevating the scalability potential of European business
Action type: Coordination and support actions
Countries involved: Spain
Call: Women TechEU (HORIZON-EIE-2022-SCALEUP-02, 2022)
Start date: 2023-07-01
End date: 2024-06-30
Duration (months): 12.0
Total project cost (EUR): 107142.86
EU funding (EUR): 75000.0
Participants: 1
Project status: CLOSED

Smallops has developed a process for the production of biogas and zero-valent iron nanoparticles encapsulated in a carbon matrix (OPS), through hydrothermal carbonization (HTC). As a synthesis method applied to vegetable water, this process results in OPS with improved characteristics compared to the reduced iron nanoparticles currently produced on the market, complying with the principles of green chemistry and, at the same time, reducing the cost of synthesis; all this within a framework of circular bioeconomy of 0 waste. The application of its process is, therefore, the synthesis of nanotechnology products (OPS) from waste generated in the olive sector, and its application in biogas production processes with the aim of (1) valuing waste from the agro-industrial and livestock sectors, (2) optimizing the production and quality of biogas produced from said residues and (3) valuing the digestate obtained as a high-quality fertilizer for application in cultivated soils. By means of this call, Smallops intends to develop a project with which to scale the growth of its company, under the fulfillment of the following objectives: - Facilitate the entry of Smallops into potential clients by establishing a mutual collaboration relationship from which both parties benefit. - Develop autonomy to offer pilots to any type of client regardless of their size and the facilities available. - Obtain metrics using mixtures of different types of raw material, making it easier to go to other biogas plants that use mixtures similar to those of the olive sector, being able to skip the initial testing phase and converting them directly into customers. O4. Ensure the development of the business in the medium term, adapting and consolidating the business plan and the company's growth strategy, based on future technological developments.

Keywords: olive mill wastewater,nanoparticles encapsulated ops,biogas production,hydrothermal carbonization